Zaltrap 200mg/8ml Infusion
Aflibercept
25mg/ml
Sanofi Aventis Groupe
| Pack size | 8ml Glass Vial |
|---|---|
| Dispensing mode | POM |
| Source | FRANCE |
| Agent | CITY MEDICAL STORE |
| Retail Price | 3743.50 AED |
Available as:
Indications
Zaltrap 200mg/8ml Infusion is used for:
The opthalmic agent is used for the treatment of neovascular (wet) age-related mascular degeneration (AMD) and macular edema following central retinal vein occulsion (CRVO). The systemic injection, known as ziv-aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Aflibercept :
Mechanism of Action
Ablibercept is a recombinant fusion protein that acts as a decoy receptor for the ligands, vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF). It prevents these ligands to binding to endothelial receptors, VEGFR-1 and VEGFR-2, to suppress neovascularization and decrease vascular permeability. This ultimately will slow vision loss or the progression of metastatic colorectal cancer.
Note
Zaltrap 200mg/8ml 25mg/ml Infusion manufactured by Sanofi Aventis Groupe. Its generic name is Aflibercept. Zaltrap 200mg/8ml is availble in United Arab Emirates.
Farmaco UAE drug index information on Zaltrap 200mg/8ml Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.